Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial

Caroline Bodet-Milin; Alain Faivre-Chauvet; Thomas Carlier; Aurore Rauscher; Mickael Bourgeois; Evelyne Cerato; Vincent Rohmer; Olivier Couturier; Delphine Drui; David M. Goldenberg; Robert M. Sharkey; Jacques Barbet; Francoise Kraeber-Bodere

doi:10.2967/jnumed.116.172221

Research ArticleClinical Investigations

Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ⁶⁸Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial

Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, Aurore Rauscher, Mickael Bourgeois, Evelyne Cerato, Vincent Rohmer, Olivier Couturier, Delphine Drui, David M. Goldenberg, Robert M. Sharkey, Jacques Barbet and Francoise Kraeber-Bodere

Journal of Nuclear Medicine October 2016, 57 (10) 1505-1511; DOI: https://doi.org/10.2967/jnumed.116.172221

Caroline Bodet-Milin

1Nuclear Medicine Department, University Hospital, Nantes, France

2CRCNA, Inserm U892, CNRS UMR 6299, Nantes, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alain Faivre-Chauvet

1Nuclear Medicine Department, University Hospital, Nantes, France

2CRCNA, Inserm U892, CNRS UMR 6299, Nantes, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thomas Carlier

1Nuclear Medicine Department, University Hospital, Nantes, France

2CRCNA, Inserm U892, CNRS UMR 6299, Nantes, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Aurore Rauscher

2CRCNA, Inserm U892, CNRS UMR 6299, Nantes, France

3Nuclear Medicine, ICO Cancer Center, Saint-Herblain, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mickael Bourgeois

1Nuclear Medicine Department, University Hospital, Nantes, France

2CRCNA, Inserm U892, CNRS UMR 6299, Nantes, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Evelyne Cerato

1Nuclear Medicine Department, University Hospital, Nantes, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vincent Rohmer

4Endocrinology Department, University Hospital, Angers, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Olivier Couturier

5Nuclear Medicine, University Hospital, Angers, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Delphine Drui

6Endocrinology Department, University Hospital, Nantes, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David M. Goldenberg

7IBC Pharmaceuticals, Inc., Morris Plains, New Jersey

8Immunomedics, Inc., Morris Plains, New Jersey; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Robert M. Sharkey

8Immunomedics, Inc., Morris Plains, New Jersey; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jacques Barbet

2CRCNA, Inserm U892, CNRS UMR 6299, Nantes, France

9GIP Arronax, Saint-Herblain, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Francoise Kraeber-Bodere

1Nuclear Medicine Department, University Hospital, Nantes, France

2CRCNA, Inserm U892, CNRS UMR 6299, Nantes, France

3Nuclear Medicine, ICO Cancer Center, Saint-Herblain, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 57, Issue 10

October 1, 2016

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ⁶⁸Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial

Journal of Nuclear Medicine Oct 2016, 57 (10) 1505-1511; DOI: 10.2967/jnumed.116.172221

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Journal of Nuclear Medicine Oct 2016, 57 (10) 1505-1511; DOI: 10.2967/jnumed.116.172221

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

Pretargeting: A Path Forward for Radioimmunotherapy
Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Pretargeted Imaging and Therapy
PET Imaging for Endocrine Malignancies: From Woe to Go

Google Scholar

Keywords

medullary thyroid carcinoma
immuno-PET
pretargeting
bispecific antibody
68Ga
pharmacokinetics

Main menu

User menu

Search

Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ⁶⁸Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords